Patents by Inventor Arturo Jose Vegas
Arturo Jose Vegas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230124955Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: ApplicationFiled: August 23, 2022Publication date: April 20, 2023Applicant: Massachusetts Institute of TechnologyInventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Patent number: 11458158Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: GrantFiled: May 5, 2020Date of Patent: October 4, 2022Assignee: Massachusetts Institute of TechnologyInventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Patent number: 11446239Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: GrantFiled: September 17, 2020Date of Patent: September 20, 2022Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
-
Publication number: 20210069100Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: ApplicationFiled: September 17, 2020Publication date: March 11, 2021Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
-
Patent number: 10835486Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: GrantFiled: December 15, 2016Date of Patent: November 17, 2020Assignees: Massachusetts Institute of Technology, The Children's Medical Center CorporationInventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Arturo Jose Vegas, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup
-
Publication number: 20200330501Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: ApplicationFiled: May 5, 2020Publication date: October 22, 2020Applicant: Massachusetts Institute of TechnologyInventors: Yizhou Dong, Kevin Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Patent number: 10786446Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: GrantFiled: November 26, 2018Date of Patent: September 29, 2020Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
-
Patent number: 10682374Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: GrantFiled: September 10, 2018Date of Patent: June 16, 2020Assignee: Massachusetts Intstitute of TechnologyInventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Publication number: 20190091139Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: ApplicationFiled: November 26, 2018Publication date: March 28, 2019Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
-
Publication number: 20190076462Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: ApplicationFiled: September 10, 2018Publication date: March 14, 2019Applicant: Massachusetts Institute of TechnologyInventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Patent number: 10172791Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: GrantFiled: March 14, 2014Date of Patent: January 8, 2019Assignee: Massachusetts Institute of TechnologyInventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
-
Publication number: 20180353643Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: ApplicationFiled: May 17, 2016Publication date: December 13, 2018Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Arturo Jose Vegas, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup
-
Patent number: 10086013Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: GrantFiled: November 1, 2016Date of Patent: October 2, 2018Assignee: Massachusetts Institute of TechnologyInventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Patent number: 9970002Abstract: Provided are derivatized therapeutic, prophylactic, or diagnostic agents, such as nucleic acids, that can be effectively delivered to cells and tissues. Also provided are methods of affecting a biological process by administering a therapeutic, prophylactic, or diagnostic agent, such as functional nucleic acid, to a cell or a subject, where the therapeutic, prophylactic, or diagnostic agent, such as functional nucleic acid, is derivatized therapeutic, prophylactic, or diagnostic agent, such as nucleic acid.Type: GrantFiled: December 12, 2013Date of Patent: May 15, 2018Assignees: Massachusetts Institute of Technology, The Children's Medical Center CorporationInventors: Daniel G. Anderson, Rosemary Lynn Kanasty, Arturo Jose Vegas, Robert S. Langer
-
Publication number: 20180036333Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: ApplicationFiled: November 1, 2016Publication date: February 8, 2018Applicant: Massachusetts Institute of TechnologyInventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Patent number: 9872911Abstract: ?-Aminoamidine polymers and methods of preparing a-aminoamidine polymers by reacting by reacting one or more amines with one or more isocyanides and one or more aldehydes are described. Methods of preparing a-aminoamidine polymers from commercially available starting materials are also provided, wherein the starting materials are racemic or stereochemically pure. a-Aminoamidine polymers or salt forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems and for other purposes as well such as, for example, coatings, additives, excipients, plastics, and materials, etc. Given the amino moiety of these ?-aminoamidine polymers, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive ?-aminoamidine polymers and polynucleotides can be prepared. The inventive ?-aminoamidine polymers may also be used in preparing microparticles for drug delivery.Type: GrantFiled: December 15, 2012Date of Patent: January 23, 2018Assignee: Massachusetts Institute of TechnologyInventors: Arturo Jose Vegas, Kathryn Ann Whitehead, Daniel Griffith Anderson, Robert S. Langer, Joseph R. Dorkin
-
Patent number: 9867869Abstract: Compounds, compositions, and methods for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through glucose-sensing insulin derivatives, are provided. The insulin derivatives bind serum albumin or agglomerate in vivo. The insulin derivatives effectively dissociate to release insulin in a hyperglycemic condition, where the complexation of glucose to a glucose-sensing element alters properties of the insulin derivative leading to the dissociation. The compounds, compositions, and methods provide a delivery strategy for both self-regulated and long-term diabetes management.Type: GrantFiled: December 12, 2013Date of Patent: January 16, 2018Assignees: Massachusetts Institute of Technology, The Children's Medical Center CorporationInventors: Daniel G. Anderson, Hung-Chieh Chou, Michael J. Webber, Benjamin C. Tang, Yair Levi, Yunlong Zhang, Rosemary Lynn Kanasty, Arturo Jose Vegas, Robert S. Langer
-
Publication number: 20170165290Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: ApplicationFiled: November 1, 2016Publication date: June 15, 2017Applicant: Massachusetts Institute of TechnologyInventors: Yizhou Dong, Kevin Thomas Love, Robert S. Langer, Daniel Griffith Anderson, Delai Chen, Yi Chen, Arturo Jose Vegas, Akinleye C. Alabi, Yunlong Zhang
-
Publication number: 20170152213Abstract: Provided herein are lipidoids that may be prepared from the conjugate addition of alkylamines to acrylates. In some embodiments, provided lipidoids are biodegradable and may be used in a variety of drug delivery systems. Given the amino moiety of the lipidoids, they are well-suited for the delivery of polynucleotides, in addition to other agents. Nanoparticles containing the inventive lipidoids and polynucleotides have been prepared and have been shown to be effective in delivering siRNA.Type: ApplicationFiled: September 13, 2016Publication date: June 1, 2017Applicant: Massachusetts Institute of TechnologyInventors: Daniel Griffith Anderson, Kathryn Ann Whitehead, Joseph A. Dorkin, Arturo Jose Vegas, Yunlong Zhang, Robert S. Langer
-
Publication number: 20170095514Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.Type: ApplicationFiled: December 15, 2016Publication date: April 6, 2017Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Arturo Jose Vegas, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup